Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong, China.
Transl Neurodegener. 2013 Sep 8;2(1):19. doi: 10.1186/2047-9158-2-19.
There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B (MAOB) inhibitors. They have been studied for their potential disease-modifying effects in Parkinson's disease (PD) for over 20 years in various clinical trials. This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD. Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug. Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles, some of which may be insurmountable.
有大量来自帕金森病动物模型的实验证据表明，单胺氧化酶-B（MAOB）抑制剂具有神经保护作用。在过去的 20 多年里，人们在各种临床试验中研究了它们在帕金森病（PD）中的潜在疾病修饰作用。本综述总结了这些临床试验，并讨论了其结果在 PD 疾病修饰中的意义。早期关于司来吉兰的临床试验受到该药物对症治疗作用的干扰。后来使用延迟启动设计的雷沙吉兰临床试验为 PD 的疾病修饰提供了新的见解，但由于一些障碍，这一策略的目标仍然难以实现，其中一些障碍可能是无法克服的。
